Repurposed-medicine education

Research Overviews

Professional, evidence-aware introductions to four medicines frequently discussed in repurposed-drug cancer research.

Ivermectin Fenbendazole Mebendazole Methylene Blue

Human antiparasitic · Preclinical oncology research

Ivermectin: An Overview

Ivermectin is a macrocyclic-lactone antiparasitic derived from avermectins discovered through work by Satoshi Ōmura and William C. Campbell. Their discoveries transformed treatment of parasitic diseases and were recognized with the 2015 Nobel Prize in Physiology or Medicine.

Effects explored in cancer research

Laboratory and animal studies have investigated effects on cancer-cell proliferation, programmed cell death, migration, angiogenesis and drug resistance. These findings are preclinical; ivermectin is not established as a cancer treatment in human clinical trials.

Potential uses under study

Approved or established treatment of specified parasitic infections
Inhibition of tumor-cell growth in laboratory models
Induction of apoptosis and autophagy in experimental systems
Possible modulation of drug-resistance pathways in preclinical models

Mechanisms discussed in the literature

Antiparasitic action

Activation of parasite glutamate-gated chloride channels causes paralysis and death of susceptible parasites.

Growth signaling

Experimental work has examined PAK1, Wnt/TCF and Akt/mTOR signaling involved in proliferation and survival.

Cell death

Preclinical models report mitochondrial stress, reactive oxygen species and activation of apoptosis or autophagy pathways.

Drug resistance

Laboratory studies have explored P-glycoprotein activity and immune effects that could alter treatment sensitivity.

Veterinary anthelmintic · Preclinical oncology research

Fenbendazole: An Overview

Fenbendazole is a benzimidazole anthelmintic introduced for veterinary use in the 1970s. It disrupts parasite microtubules and remains intended for animal health; it is not approved as a human cancer therapy.

Effects explored in cancer research

Cell-culture and animal studies have evaluated growth inhibition, apoptosis, glucose metabolism and interactions with chemotherapy. Human evidence is sparse, and patient reports cannot determine effectiveness.

Potential uses under study

Treatment of specified parasitic infections in animals
Disruption of cancer-cell division in laboratory systems
Activation of programmed cell death in preclinical models
Changes in tumor growth in some animal studies
Experimental combinations with cytotoxic medicines

Mechanisms discussed in the literature

Antiparasitic action

Binding to tubulin impairs microtubule formation and nutrient uptake in susceptible parasites.

Cell division

Experimental cancer models examine moderate microtubule destabilization and mitotic arrest.

Programmed cell death

Preclinical reports describe p53-related signaling, mitochondrial stress and caspase activation in some cell lines.

Metabolism and combinations

Animal and laboratory work has explored glucose transport, hexokinase activity and additive effects with agents such as docetaxel.

Human anthelmintic · Preclinical and early clinical research

Mebendazole: An Overview

Mebendazole is a benzimidazole antiparasitic developed by Janssen Pharmaceutica and introduced in the early 1970s. It is used in humans for specified intestinal worm infections and appears on the World Health Organization’s Model List of Essential Medicines.

Effects explored in cancer research

Preclinical studies have examined cancer-cell proliferation, migration, angiogenesis, microtubules and programmed cell death. Early clinical investigation exists for selected cancers, but robust evidence of anticancer benefit in humans remains limited.

Potential uses under study

Treatment of specified intestinal nematode infections
Suppression of tumor-cell proliferation in laboratory models
Induction of apoptosis and autophagy in experimental systems
Possible alteration of chemotherapy resistance pathways

Mechanisms discussed in the literature

Antiparasitic action

Binding to β-tubulin disrupts microtubules, glucose uptake and cellular transport in susceptible worms.

Growth signaling

Experimental studies have examined G2/M arrest and Hedgehog, Wnt/β-catenin and NF-κB pathways.

Cell death

Laboratory findings include mitochondrial depolarization, cytochrome-c release, oxidative stress and autophagy.

Drug resistance

Preclinical research has explored P-glycoprotein efflux and possible effects on the tumor microenvironment.

Approved medical dye and antidote · Experimental oncology research

Methylene Blue: An Overview

Methylene blue is a synthetic phenothiazine dye first produced by Heinrich Caro in 1876. It later became a medical staining agent and treatment for acquired methemoglobinemia, and its redox and photosensitizing properties prompted broader research.

Effects explored in cancer research

Preclinical studies have evaluated mitochondrial metabolism, oxidative stress, apoptosis and photodynamic therapy. Light-activated methylene blue can generate reactive oxygen species locally, but anticancer use remains experimental.

Potential uses under study

Treatment of acquired methemoglobinemia in appropriate patients
Alteration of cancer-cell metabolism in laboratory models
Induction of oxidative stress and apoptosis experimentally
Use as a photosensitizer in photodynamic research
Experimental sensitization to radiation or chemotherapy

Mechanisms discussed in the literature

Methemoglobinemia

Through an NADPH-dependent pathway, methylene blue helps reduce methemoglobin back toward functional hemoglobin.

Cell metabolism

Laboratory studies investigate mitochondrial electron cycling and shifts between glycolytic and oxidative metabolism.

Cell death

Experimental oxidative stress can damage mitochondria and activate apoptosis-related pathways.

Photodynamic action

Red-light activation can produce singlet oxygen and other reactive species, creating localized cell damage in model systems.

Research information is not a prescription

These summaries do not establish a treatment protocol, dose, combination or expected outcome. Veterinary products should not be used in humans. Medication risks, interactions and contraindications require review by an appropriately licensed treating clinician.

View Research Library